This finding suggested that the PDL1 status is not a good enough biomarker for base treatment decisions, and as such, pembrolizumab trials in gastric and GEJ adenocarcinoma are still ongoing. Here, CD274 is linked to gastroesophageal junction adenocarcinoma.